Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

1.300 -0.100 (-7.14%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 670,721
Open 1.350
Bid (Size) 1.300 (11)
Ask (Size) 1.410 (6)
Prev. Close 1.400
Today's Range 1.290 - 1.370
52wk Range 1.110 - 11.26
Shares Outstanding 54,933,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
From The Law Offices of Frank R. Cruz
Via Business Wire

Performance

YTD
-87.50%
-87.50%
1 Month
+7.44%
+7.44%
3 Month
-13.91%
-13.91%
6 Month
-86.97%
-86.97%
1 Year
-87.93%
-87.93%

More News

Read More
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
From Faruqi & Faruqi LLP
Via GlobeNewswire
MRNS DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS
From The Rosen Law Firm PA
Via GlobeNewswire
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
From Marinus Pharmaceuticals
Via Business Wire
MRNS DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Marinus Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 5 Deadline in Securities Class Action First Filed by the Firm – MRNS
From The Rosen Law Firm PA
Via GlobeNewswire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024
From Berger Montague
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Humana, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS
From The Rosen Law Firm PA
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
From Faruqi & Faruqi LLP
Via GlobeNewswire
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS
From The Rosen Law Firm PA
Via GlobeNewswire
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
MARINUS PHARMACEUTICALS, INC. (NASDAQ: MRNS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Marinus Pharmaceuticals, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, and Lamb Weston and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.